All posts

Trulieve Cannabis gets price target raised to $36.00 at Beacon

Following the company’s first quarter results, Beacon Securities analyst Russell Stanley has raised his price target on Trulieve Cannabis (Trulieve Cannabis Stock Quote, Chart CSE:TRUL).

This morning, Trulieve reported its Q1, 2019 results. The company posted EBITDA of $19.0-million on revenue of $44.5-million, a topline that was up 192 per cent over the same period last year.

“Our first quarter results reflect our ability to deliver on our strategic initiatives, translating into continued strong financial performance,” CEO Kim Rivers said. “In addition to delivering on strong financial results, we also achieved many significant milestones in the first quarter of the year. Growth continued in Florida with the opening of four new dispensaries, completing the first sale of smokable flower in Florida and settling with the Florida Department of Health, allowing us an additional 14 stores above the state cap. We are very pleased with the progress we experienced in the beginning of 2019 and are continuing to see that same momentum carry into the second quarter.”

As a result of today’s news, Stanley has raised his one-year price target on the stock to $36.00 (from $32.00). The analyst explained his reasoning in a note to clients.

“TRUL reported quarterly results that beat our forecast as well as consensus estimates across the board, Stanley said. “The company also introduced updated guidance earlier than we expected, demonstrating confidence in the business outlook following the increase in the company’s dispensary cap, and the legalization of smokable cannabis products in Florida. We have increased our F2020E EBITDA forecast from $142M to $157M, which is near the high end of management’s guidance range ($140M to $160M, see page 4 for more detail), although we believe there is additional upside potential to this guidance. We continue to value TRUL using a 20x EV/2020E EBITDA multiple, which takes our 12-month target price to C$36/sh from C$32/sh.”

Stanley thinks TRUL will post Adjusted EBITDA of $98.6-million on revenue of $231.6-million in fiscal 2019. He expects those numbers will improve to EBITDA of $157.0-million on a topline of $390.6-million the following year.

Stanley new target represented a return of 119 per cent at the time of publication.

“Trulieve now trades at 10x our 2020E EBITDA forecast. This represents a 55% discount to the 22x at which the broad peer group trades, and a 68% discount to the 31x average amongst companies with a C$1+ market capitalization,” the analyst adds.

Tagged with: trul
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Should you sell your Salesforce.com stock?

Roth Capital Markets analyst Richard Baldry maintained a “Buy” rating and US$395.00 price target on Salesforce (Salesforce Stock Quote, Chart, News,… [Read More]

6 hours ago

RBC says weak jobs report puts pressure on Bank of Canada to lower rates

Canada shed 66,000 jobs in August, marking a second straight monthly contraction and pushing the unemployment rate up to 7.1%,… [Read More]

1 day ago

CAE named “Top Pick” by this fund manager

Rebecca Teltscher, Portfolio Manager at Newhaven Asset Management, told BNN Bloomberg’s Market Watch on Sept. 3 that she sees long-term… [Read More]

1 day ago

Buy this “down in the dumps” Canadian stock, fund manager says

Barry Schwartz, president and chief investment officer at Baskin Wealth Management, told BNN Bloomberg’s Market Watch on Sept. 2 that… [Read More]

2 days ago

AI saved Google’s search monopoly, this analyst says

Roth Capital Markets analyst Rohit Kulkarni maintained a “Buy” rating and US$210.00 target price on Alphabet (Alphabet Stock Quote, Chart,… [Read More]

2 days ago

Is Perimeter Medical Imaging a buy?

Paradigm Capital analyst Scott McAuley maintained a “Speculative Buy” rating but lowered his target price for Perimeter Medical Imaging AI… [Read More]

2 days ago